How Weight Loss Drugs Change Consumer Behavior and Business

While big pharmaceutical innovations have been transforming health outcomes for decades, signs are now beginning to emerge that weight-loss drugs like Ozempic and Wegovy may be changing something even bigger: the economics of consumption.

Originally developed to treat diabetes and now widely prescribed for weight loss, these drugs are influencing not only physical health and body size, but also collective behavior — how people eat, shop, move, perceive themselves and make decisions — with profound implications for business leaders.

Also read:

Based on early signs, weight-loss drugs may be catalyzing a behavioral and economic transformation comparable to major technological advances.

Consumer interest in Ozempic, for example, has grown faster than searches for the iPhone and other popular technology products. But unlike digital innovations, this disruption is physiological — a transformation that begins in biology and spreads to sectors previously distant from health, blurring boundaries between food, wellness, beauty, retail and tourism.

Medicines are changing how families spend

A PwC analysis, based on data from Numerator, shows that users of these medications eat less — and this reduction in appetite leads to lower overall consumption. Among more than 11,000 U.S. households, grocery spending fell 6% to 8% in the first 12 months when the user was the primary grocery buyer — a sharp pullback in an industry that typically changes slowly and predictably.

At the same time, total household spending fell just 2% to 3%, indicating that some of those savings were redirected to other categories.

Consumer identity, habits and priorities are being redefined

The effects of these medications are not limited to the food industry. Changes also appear in adjacent sectors.

In clothing, spending increases by 4% to 5% approximately six months after starting treatment. Some of this reflects wardrobe replacement, but many users report renewed confidence and a desire to align appearance and well-being — preferring fitted, expressive, and sporty clothing.

The same goes for fitness. Gym memberships and equipment purchases increase right at the beginning of treatment, signaling a wave of motivation to exercise. Even if enthusiasm diminishes over time, there is a repositioning of priorities, focusing on routine and maintaining health, rather than performance.

Eating habits are also evolving: while spending on fast food and snacks falls, consumption in full-service restaurants grows. People are eating less but investing more in social meals and intentional experiences.

There are similar signs in tourism: wellness vacations and fitness retreats are on the rise — and even airlines may burn less fuel as the average body weight of passengers drops.

How far will the chain effects go?

In a broader data set of nearly 100,000 households, 14% say they currently use a weight-loss medication, and another 24% would consider doing so if factors such as cost, insurance coverage, and alternative formats (such as pills) improved.

Additionally, these medications are increasingly being prescribed for other health conditions, such as fertility, addiction, and even heart disease. This leaves room for accelerated adoption, especially as costs decrease, formulations evolve, and public awareness grows.

The scope of the effects is still uncertain, but the impacts could extend to sectors such as beauty, fitness, hospitality and life insurance. And new questions arise: What will happen to industries based on indulgence, convenience or entertainment if people’s appetite, motivation and self-image change on a large scale?

Even digital dating platforms are adapting to new ways of self-presentation and user priorities. Alcohol and entertainment companies may also feel the impact, as social rituals shaped by food and drink transform.

Planning, not forecasting

Executives don’t need to react to every headline about weight-loss drugs, but they should adopt a model of understanding and planning for how consumer behaviors are changing — and where these changes may create risks or opportunities.

It’s not about predicting the future, but about planning scenarios: identifying which consumer habits are vulnerable, which aspirations are emerging and which areas of the business are least prepared for a demand curve that is being rewritten in real time.

Based on our experience with companies that are already dealing with the topic, three actions stand out:

1. Evaluate and map the areas of the business already affected, even with incomplete data.

2. Project two- to three-year scenarios, exploring how behavioral changes can impact the current business and reveal new opportunities.

3. Train teams to understand the behavioral transformations of this growing audience.

Companies that deeply analyze new search, purchase and consumption patterns will be at an advantage.

How far will weight loss drugs go?

The effects of use are already rewriting demand across sectors — from retail and food to insurance and wellness. The current 14% penetration is just the beginning. As cost, access and format barriers fall, adoption is expected to accelerate, expanding the economic and strategic implications.

This is not a passing trend. Weight-loss medications are driving a profound shift in human behavior, altering how people think about themselves and what they buy. When biological changes occur at scale, consumption patterns also change.

Leaders who take this seriously — integrating real-time health data and demand forecasts to adapt products and services — can shape the next era of value creation.

The focus should be on planning for multiple scenarios, not predicting a single outcome.

The question is not whether this biological transformation will affect your industry — our data shows that it is already happening.

The real question is: Will your organization be able to lead with intelligent adaptation, or will it respond to competitors who first understand that, in the new economy of appetite, whoever deciphers shifts in consumer priorities fastest captures the greatest value?

c.2025 Harvard Business Review. Distribuído pela New York Times Licensing